Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03906448 · ClinicalTrials.gov registry record · Phase 2
FORWARD Optune and Adjuvant TMZ in Grade II/III Astrocytoma
A Phase 2 study, sponsored by University of Florida.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT03906448: Clinical Trial Phase 2 study, sponsored by University of Florida.
NCT03906448 is a Phase 2 study that was terminated before completion, run by University of Florida. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03906448, a Phase 2 study, was terminated before completion, sponsored by University of Florida.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a phase 2, multi-institutional, historically-controlled, study of 100 patients with newly diagnosed Grade II and III astrocytoma comparing the combination of TTFields with adjuvant temozolomide versus temozolomide alone in historical controls after the completion of definitive chemoradiotherapy. Study treatment may continue past first tumor recurrence. The primary endpoint will be overall survival.
Primary Outcome
Frequency of overall survival in study participants. 2 years of active treatment, lifelong survival follow-up.
Interventions
- COMBINATION_PRODUCT TTFields with adjuvant temozolomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2019-05-20 |
| Est. Completion | 2020-06-08 |
| Phase | Phase 2 |
Why NCT03906448 stopped before completion
NCT03906448 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which TTFields with adjuvant temozolomide is the first listed.
NCT03906448 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03906448 about?
NCT03906448 is a clinical study titled "FORWARD Optune and Adjuvant TMZ in Grade II/III Astrocytoma". This is a phase 2, multi-institutional, historically-controlled, study of 100 patients with newly diagnosed Grade II and III astrocytoma comparing the combination of TTFields with adjuvant temozolomide versus temozolomide alone in historical controls after the completion of definitive chemoradiother...
What is the current status of trial NCT03906448?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2019-05-20. Estimated completion is 2020-06-08.
What interventions are being tested in trial NCT03906448?
The interventions under investigation include: TTFields with adjuvant temozolomide (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03906448?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03906448's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI